@OmicronData 1. The number of cases is way understated, this is not even close to 12%, might be closer to 1-2%.
2. The criteria for 'high risk' are not strict. It's only in the youngest and healthiest that trial didn't show a clear benefit (but did show weak indiciation of benefit).
@OmicronData 1。病例数量被低估了，甚至不接近12%，可能接近1-2%。
2、“高风险”的标准不严格。只有在最年轻和最健康的人群中，试验才没有显示出明显的益处（但确实显示出微弱的益处迹象）。